Milestone Pharmaceuticals recorded a net loss of $28.6 million, translating to an EPS of $-0.21 for the second quarter. Investors should note that despite increasing losses, the company is expanding insurance coverage for its CARDAMYST product, potentially driving future Revenue growth.
Key Highlights
- Milestone has recently achieved a noteworthy increase in insurance coverage for its etripamil nasal spray, branded as CARDAMYST.
- As of June 30, 2026, Milestone reported $170.6 million in cash, short-term investments, and cash equivalents, a significant increase from $106 million at the end of 2025.
- The first patient is expected to be enrolled in the second half of 2026, and the outcome could significantly affect the company’s trajectory.
Milestone Pharmaceuticals Inc. (NASDAQ: MIST) announced a net loss of $28.6 million for the second quarter ending June 30, resulting in an EPS of $-0.21, which slightly missed the consensus estimate of $-0.20. This marks a significant escalation from a loss of $13 million in the same quarter last year. The company's shares have tumbled 44.7% year-to-date, reflecting investor concerns about operational performance amid rising expenditures.
With a current market Capitalization of $158 million, Milestone’s financial health is critical as it navigates market challenges while launching innovative products.
Expanded Insurance Coverage
Milestone has recently achieved a noteworthy increase in insurance coverage for its etripamil nasal spray, branded as CARDAMYST. This expansion in coverage is vital for increasing prescription uptake, which has already seen a substantial rise since its launch. The growth in prescribers is promising: over 800 unique prescribers have initiated treatment for more than 1,300 patients, significantly larger than the 200 prescribers noted earlier in the year.
As this trend grows, there is considerable potential for accelerating revenue generation in the months ahead.
Financial Position and Cost Management
As of June 30, 2026, Milestone reported $170.6 million in cash, short-term investments, and cash equivalents, a significant increase from $106 million at the end of 2025. This bolstered cash position is expected to provide sufficient runway for operational expenditures into the second half of 2027. However, selling, general, and administrative expenses surged to $22.6 million, highlighting the costs associated with the product launch.
While Research and Development costs decreased slightly to $3.5 million, the overall increase in expenses signals a critical juncture for the company’s financial stewardship as it balances growth initiatives with sustained losses.
Future Growth Catalyst
The first patient is expected to be enrolled in the second half of 2026, and the outcome could significantly affect the company’s trajectory. The results from this trial not only shape future revenues but also support the long-term viability of CARDAMYST in an adjacent cardiovascular market. Investors will be keenly watching for updates from the upcoming European Society of Cardiology Congress on August 28-31, where Milestone will present further insights into its research advancements.






Please wait processing your request...